A Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Latest Information Update: 16 Aug 2023
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Agitation
- Focus Therapeutic Use
- Sponsors BioXcel Therapeutics
- 09 Aug 2023 Planned End Date changed from 24 Jun 2023 to 31 Jul 2024.
- 09 Aug 2023 Planned primary completion date changed from 24 Jun 2023 to 31 Jul 2024.
- 26 Sep 2022 Planned number of patients changed from 120 to 140.